2023年7月14日

西奈加速器欢迎十个健康技术员公司全球第九类加速器。这些企业正在建造各种各样的医疗解决方案监控设备对于脓毒症,心力衰竭和中风虚拟现实游戏旨在帮助孩子管理在医疗过程痛苦和焦虑。在三个月的计划,公司领导从西奈研究者获得实践经验和指导,管理员,和临床医生,开发和完善他们的产品和解决方案的实际应用。随着个性化指导,每个公司将获得100000美元的投资从西奈。和三个月的项目完成后,公司领导人将与观众分享他们的进步的投资者,导师,潜在客户,和新闻媒体成员演示的一天。第九西奈加速器类包括:- 52北-剑桥,英国的公司52北健康发展医院外的医疗设备,患者可以使用监控粒细胞减少性脓毒症的风险,危及生命的并发症的化疗。Neutrocheck设备提供家庭测试使用血液从一个小针孔。- Acorai -斯德哥尔摩,瑞典公司Acorai为心脏衰竭开发设备管理通过无创性心脏内的压力监测,帮助减少住院和再入院。Acorai心脏监测结合地震、音频、视觉、和电子传感器,实时捕捉和分析数据使用机器学习。 — Alva Health – New Haven, Connecticut-based Alva Health develops wearable monitoring devices for early stroke detection. The system uses machine learning to monitor the onset of hemiparesis (paralysis on one side of the body). When the system detects a stroke, the device notifies the user immediately. If there is no response from the user, the device can connect users with emergency responders. — CARI Health – San Diego, California-based CARI Health develops a remote medication monitor to enable personalized dosing and real-time medication adherence monitoring. CARI’s solution combines proprietary core sensing technology with just-in-time intervention software, mobile apps, data, and AI to detect medication levels in real-time. — equalityMD – Richmond, Virginia-based equalityMD develops a community-centric platform for LGBTQ+ patients to share and connect with others. The platform also provides telehealth services by connecting to clinicians, enabling LGBTQ+ patients to share their experiences and foster a true sense of community around health and wellness. — Machine Medicine – London, U.K.-based Machine Medicine develops a platform that helps researchers capture and assess motor functioning in patients with neuromodulation devices. KELVIN (the software component) enables anyone to do a motor assessment remotely via their smartphone, allowing faster and more frequent patient monitoring. — Paperplane Therapeutics – Quebec, Canada-based Paperplane Therapeutics designs therapeutic virtual reality video games to improve pain and anxiety management in children undergoing various medical treatments or procedures. — Predicta Med – Ramat Gan, Israel-based Predicta Med develops a solution for early detection and treatment selection for undiagnosed autoimmune diseases. Predicta Med’s deep learning engine aggregates electronic medical records and claims data. It enriches and analyzes this data to identify patients at risk of autoimmune diseases and provide actionable insights for optimal intervention. — RCE.ai – Carlsbad, California-based RCE Technologies develops a noninvasive device that monitors cardiac proteins in the blood, empowering emergency medicine physicians and cardiologists to assess patients presenting with chest pain early. — TestDynamics – Austin, Texas-based TestDynamics develops a platform that offers hospitals and physicians one-stop, intelligent access to a wide range of AI models for medical imaging. It aims to improve patient care outcomes, reduce healthcare costs, and lower malpractice risk. KEY QUOTES: “I’m excited to welcome these innovative teams from around the globe who are developing new technologies which have the promise to enhance the delivery of efficient and cost-effective patient care.” — James Laur, JD, vice president of Intellectual Property, managing director of Cedars-Sinai Technology Ventures, and one of the accelerator’s founders “The provision of strategic and operational insights at the outset of development plays a pivotal role in driving healthcare innovations, and each accelerator class brings that opportunity to the Cedars-Sinai community. With our next class, we are looking forward to continuing to transform healthcare and research here in Los Angeles and beyond.” — Nirdesh K. Gupta, Ph.D., managing director of Cedars-Sinai Technology Ventures Trending on Pulse 2.0